Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients

Cancer

Volumn 117, Issue 14, 2011, Pages 3156-3162

  Shulman, Katerina ^a,b   Cohen, Ilana ^a   Barnett Griness, Ofra ^a   Kuten, Abraham ^b   Gruber, Stephen B ^c   Lejbkowicz, Flavio ^a   Rennert, Gad ^a,d  

^a CLALIT HEALTH SERVICES   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c UNIVERSITY OF MICHIGAN   (United States)

^d CARMEL MEDICAL CENTER   (Israel)

Author keywords

colorectal cancer; irinotecan; survival; toxicity; UGT1A1

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DNA FRAGMENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGE; AGED; ALLELE; ARTICLE; BLOOD TOXICITY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; ETHNIC GROUP; ETHNICITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HOSPITALIZATION; HUMAN; INFECTION; ISRAELI; LENGTH OF STAY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; ONCOGENE; ONCOGENE UGT1A1; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TANDEM REPEAT; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; POLYMORPHISM, GENETIC;

EID: 79959965073     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25735     Document Type: Article

References (20)

1. Pizzolato JF, Saltz LB., The camptothecins. Lancet 2003; 361: 2235-2242. (Pubitemid 36782561)
2. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009; 27: 2604-2614.
3. Armand JP, Extra YM, Catimel G, Abigerges D, Marty M, Clavel M., Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol. 1996; 7: 837-842. (Pubitemid 26345875)
4. Rouits E, Charasson V, Petain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008; 99: 1239-1245.
5. Innocenti F, Ratain MJ,. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004; 75: 495-500.
6. Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 2009; 27: 2457-2465.
7. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006; 24: 3061-3068. (Pubitemid 46638941)
8. Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008; 112: 1932-1940.
9. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2: 43-47. (Pubitemid 34982202)
10. Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007; 13: 3269-3275. (Pubitemid 46944912)
11. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL., UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007; 99: 1290-1295. (Pubitemid 47394168)
12. Biason P, Masier S, Toffoli G., UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemother. 2008; 20: 158-165. (Pubitemid 351797053)
13. Rhodes KE, Zhang W, Yang D, et al. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett. 2007; 1: 23-30.
14. Ferraldeschi R, Minchell LJ, Roberts SA, et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009; 10: 733-739.
15. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer. 2006; 106: 1007-1016.
16. de Jong FA, Kehrer DF, Mathijssen RH, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind,randomized, placebo-controlled study. Oncologist. 2006; 11: 944-954. (Pubitemid 44373767)
17. FDA,,.
18. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28: 866-871.
19. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD., Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009; 11: 21-34.
20. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352: 2184-2192. (Pubitemid 40727085)